Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

tivantinib

- PMLiVE

ASCO: AZ’s ovarian cancer combination aces trial

Olaparib/cediranib combo demonstrates progression-free survival of 17.7 months

- PMLiVE

GSK and Bayer strike new biotech cancer deals

Agreements with Orion and Adaptimmune aimed at strengthening their respective oncology pipelines

- PMLiVE

Interview: AstraZeneca’s Susan Galbraith

As ASCO commences the company's VP of oncology talks to PMLiVE about its pipeline prospects in cancer

- PMLiVE

Japanese product news in brief

Home launch for Astellas' Xtandi, GSK files COPD drug for approval and more

- PMLiVE

European prescribing of new anticoagulants on the increase

Daiichi Sankyo-backed study shows doctors are turning to new drugs for VTE

- PMLiVE

Boehringer launches ASCO blog to talk about lung cancer

Not Just One Disease set to cover a range of topics, including the patient journey

Bristol-Myers Squibb (BMS) building

BMS’ nivolumab gets breakthrough status

But shares fall on concerns over new trial data

- PMLiVE

Second darapladib failure disappoints GSK

Drug unable to demonstrate effectiveness in acute coronary syndrome

- PMLiVE

Macmillan campaign for legacy donations

Cancer charity aims to raise awareness of the importance of gifts in wills

- PMLiVE

AZ starts pivotal trials of lung cancer immunotherapy

Moves MEDI4736 into phase III testing for non-small cell lung cancer

- PMLiVE

Merck’s vintafolide fails ovarian cancer trial

Major blow for drug’s original developers Endocyte

Novartis building

Novartis gets US nod for lung cancer relapse therapy Zykadia

Second ALK inhibitor to be approved after Pfizer’s Xalkori

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links